| Document |
Document Title |
|
WO/2024/083120A1 |
Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
|
|
WO/2024/085607A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2024/085354A1 |
The present invention provides, in the present specification, a heterocyclic compound and an organic light-emitting device including same.
|
|
WO/2024/085372A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device and a composition for an organic layer, each including same.
|
|
WO/2024/083255A1 |
Disclosed in the present invention are an SOS1 degradation agent and a user thereof. The present invention provides a compound as represented by formula (I), and/or a stereoisomer, an enantiomer, a diastereomer, a deuterated compound, a ...
|
|
WO/2024/084186A1 |
The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
|
|
WO/2024/085588A1 |
The present invention relates to: a compound for an organic optoelectronic device, represented by chemical formula 1; and an organic optoelectronic device and a display device which comprise the compound. The details of chemical formula ...
|
|
WO/2024/085676A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same, and, more specifically, to an organic compound having excellent electron injection and transport ability and thermal stability...
|
|
WO/2024/080361A1 |
The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The compound of the invention has excellent α1A adrenergic receptor agonist activity and is useful as a proph...
|
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
|
WO/2024/078287A1 |
The present application relates to the technical field of organic electroluminescence, and relates to an organic compound and an organic electroluminescent device and electronic apparatus using same. The organic compound has the structur...
|
|
WO/2024/080128A1 |
The present invention addresses the problem of providing an actinic ray-sensitive or radiation-sensitive resin composition from which a resist pattern having a small LWR can be formed. An actinic ray-sensitive or radiation-sensitive resi...
|
|
WO/2024/080792A1 |
Provided are a compound, selected from compounds of Formula 1, enantiomers, diastereomers, solvates and hydrates thereof, and pharmaceutically acceptable salts thereof, methods of preparing the same, and use thereof.
|
|
WO/2024/081904A1 |
This disclosure provides compounds of Formula (I), Formula (II), Formula (III), and pharmaceutically acceptable salts of any of the foregoing, that inhibit PI3Kα. These compounds are useful for treating diseases such as cancer in a subj...
|
|
WO/2024/078513A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2024/076891A1 |
Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
|
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
|
WO/2024/076117A1 |
The present invention is an organic compound used in an organic layer provided in an organic light-emitting element. In particular, when the organic compound is used in an electron blocking layer of an organic light-emitting element, it ...
|
|
WO/2024/074414A1 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein Q, R2, R3 and U are as defined herein. The invention further relates to herbicidal compositions which comprise a...
|
|
WO/2024/077216A1 |
The disclosure is directed to compounds of Formula I (I). Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
|
|
WO/2024/068950A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/071398A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
|
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
|
WO/2024/072794A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/069492A1 |
Intermediates and processes for the preparation of Relugolix, and to pharmaceutical compositions containing Relugolix manufactured by the invented processes.
|
|
WO/2024/073426A1 |
Provided dihydroquinazolinone and azadihydroquinazolinone compounds for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction.
|
|
WO/2024/069007A2 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relat...
|
|
WO/2024/073502A1 |
The present disclosure relates to novel compounds that inhibit glucose-induced degradation-deficient (GID) E3 ligase, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related ...
|
|
WO/2024/071143A1 |
The present invention provides a photoelectric conversion element that exhibits excellent quantum efficiency when having received blue light. Also provided are an imaging element, a light sensor, a compound, and a compound production met...
|
|
WO/2024/061348A1 |
The present invention provides a 1,3-cyclohexanedione compound shown in formula I, and a stereoisomer and an agrochemically acceptable salt thereof, wherein R1, R2, R3, and R4 are as defined in the description. Also disclosed are a prepa...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/058617A1 |
The present invention relates to an antiviral use of a fused heteroaryl derivative. A fused heteroaryl derivative according to the present invention exhibits excellent inhibitory activity against ANO6, and thus can be effectively used as...
|
|
WO/2024/055648A1 |
The present invention belongs to the field of organic light-emitting materials, and particularly relates to an organic compound, an organic electroluminescent device using the organic compound, and an electronic apparatus. The organic co...
|
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
|
WO/2024/059010A1 |
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
|
|
WO/2023/159307A9 |
Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
|
|
WO/2023/212599A9 |
The present Invention relates to bifunctional compounds that serve as degraders and/or inhibitors of a target protein of interest (e.g. estrogen receptor). In the present invention, the bifunctional compounds, which contain a target prot...
|
|
WO/2024/059163A1 |
The present invention relates to highly pure and crystalline compounds as starting materials and intermediates to make maralixibat and the processes of making highly pure maralixibat. The invention also relates to an amorphous form of ma...
|
|
WO/2024/055658A1 |
The present invention belongs to the technical field of organic materials, and provides a nitrogen-containing compound, an electronic element, and an electronic device. The structure of the nitrogen-containing compound is represented by ...
|
|
WO/2024/059524A1 |
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/051720A1 |
Disclosed in the present invention are a 5-pyridine-1H-indazole compound for targeted inhibition of CLK2 and a use of the compound. The compound of the present invention is a compound represented by formula (I), formula (II) or formula (...
|
|
WO/2024/052871A1 |
The object of the invention is a novel ruthenium complex of the general formula Ru-1, in which all the variable substituents have the meanings defined in the description. Also an object of the invention is a method for obtaining the ruth...
|
|
WO/2024/051784A1 |
Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
|
|
WO/2024/054866A2 |
The present disclosure provides N,N-dimethyltryptamine (N,N-DMT) derivatives of the present disclosure provides compounds of formula (I), (I-A), (I-B), (I-C), (II), (II-A), (III), and (IV), or pharmaceutically acceptable salts or deutera...
|
|
WO/2024/054832A1 |
Provided herein are compounds that act as molecular glues, inducing degradation of CK1α or CK1α/GSPT1, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and meth...
|
|
WO/2024/051766A1 |
The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...
|
|
WO/2024/049159A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2024/049067A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2024/044847A1 |
The present application relates to methods of activating serotonin receptors in a cell using indoline derivatives of general Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, as well as to treating diseas...
|
|
WO/2024/047135A1 |
Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.
|
